

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/333455325>

Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects

Article in *Addiction* · May 2019

DOI: 10.1111/add.14695

CITATIONS

0

READS

62

18 authors, including:



Dorothy Hatsukami

University of Minnesota Twin Cities

503 PUBLICATIONS 20,947 CITATIONS

[SEE PROFILE](#)



Xianghua Luo

University of Minnesota

128 PUBLICATIONS 3,494 CITATIONS

[SEE PROFILE](#)



Mei Kuen Tang

University of Minnesota Twin Cities

19 PUBLICATIONS 9 CITATIONS

[SEE PROFILE](#)



Steven G Carmella

University of Minnesota Twin Cities

243 PUBLICATIONS 7,031 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Gathering for Health [View project](#)



Perinatal toxicology and environmental medicine. [View project](#)

Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects

Dorothy K. Hatsukami^{1,2} , Xianghua Luo^{1,3} , Alisa K. Heskin¹, Mei Kuen Tang¹ , Steven G. Carmella¹, Joni Jensen¹, Jason D. Robinson⁴, Ryan Vandrey⁵, David J. Drobes⁶, Andrew A. Strasser⁷, Mustafa al'Absi⁸, Scott Leischow⁹, Paul M. Cinciripini⁴ , Joseph Koopmeiners³, Joshua Ikuemonisan¹, Neal L. Benowitz¹⁰ , Eric C. Donny¹¹ & Stephen S. Hecht¹

ABSTRACT

Aim A previous study showed significantly greater reductions in number of cigarettes smoked and biomarkers of toxicant and carcinogen exposure in smokers assigned to immediate reduction of nicotine in cigarettes to very low levels versus gradually over time or continued smoking of normal nicotine content cigarettes. This study examines the effects of these approaches on selected biomarkers associated with harmful biological effects. **Design** Three-arm, randomized controlled trial. **Setting** Ten United States academic institutional sites. **Participants** Daily smokers uninterested in quitting smoking with a mean age of 45.1 [standard deviation (SD) = 13.4] years and smoking 17.1 (SD = 8.5) cigarettes/day; 43.9% (549 of 1250) female; 60.6% (758 of 1250) white ethnicity. **Interventions** (1) Smoking cigarettes where nicotine content was immediately reduced to very low levels ($n = 503$); (2) smoking cigarettes where nicotine content was gradually reduced, with dose changes occurring monthly ($n = 498$); and (3) continued smoking with normal nicotine content cigarettes ($n = 249$). **Measurements** Smokers were assessed at baseline while smoking their usual brand cigarettes, and again at 4, 8, 12, 16 and 20 weeks. Outcomes were areas under the concentration time curve (AUC) for the period of study of biomarkers of inflammation, oxidative stress and hematological parameters. **Findings** No consistent significant differences were observed across groups (Bayes factors showing data to be insensitive), with the only exception being red blood cell size variability, which was observed to be lower in the immediate versus gradual nicotine reduction [mean difference = -0.11 ; 95% confidence interval (CI) = $-0.18, -0.04$, $P = 0.004$] and normal nicotine control groups (mean difference = -0.15 , 95% CI = $-0.23, -0.06$, $P = 0.001$). **Conclusion** It remains unclear whether switching to very low nicotine cigarettes leads to a short-term reduction in biomarkers of tobacco-related harm.

Keywords Biomarkers of biological effects, hematological parameters, immediate versus gradual nicotine reduction, inflammation, oxidative stress, reduced nicotine content cigarettes.

Correspondence to: Dorothy K. Hatsukami, 717 Delaware Street South East, Minneapolis, MN 55414, USA. E-mail: hatsu001@umn.edu

Submitted 19 November 2018; initial review completed 19 December 2018; final version accepted 21 May 2019

Please see list of authors' affiliations at the end of the paper.

INTRODUCTION

In March 2018, the US Food and Drug Administration (FDA) issued an Advanced Notice of Proposed Rulemaking to reduce nicotine in cigarettes and potentially other combusted products to minimally or non-addictive levels [1]. The goal of this rule would be to reduce the millions of lives lost to cigarette smoking by facilitating smoking cessation and preventing the progression from experimentation with cigarettes to daily smoking or dependence [2]. One question raised by the FDA was whether reducing nicotine in cigarettes by a target date or a more gradual (or step-down) nicotine reduction approach would result in differing outcomes. In prior studies, significant reductions

in biomarkers of exposure to harmful tobacco and smoke constituents (e.g. tobacco-specific nitrosamines, volatile organic compounds) were observed when smokers who were assigned to immediate reduction to very low nicotine content (VLNC) cigarettes were compared to smokers assigned to gradual nicotine reduction [3] or normal nicotine content cigarettes [4,5]. This reduction in biomarkers of exposure was due largely to the reduction in cigarettes per day observed in the immediate reduction condition. Reductions in nicotine content in cigarettes have not resulted in significant compensatory smoking behavior [3,6,7], except when examining acute effects [8]. To date, few studies have examined the effects of VLNC cigarettes on biomarkers of biological effect ('measurement of an effect due to

exposure; these include early biological effects, alterations in morphology, structure or function and clinical systems consistent with harm') [9], such as inflammation and oxidative damage.

The interrelated phenomena of inflammation and oxidative damage are important mechanistic aspects in diseases such as cancer, chronic obstructive pulmonary disease and cardiovascular disease caused by cigarette smoking [10,11]. Inflammation and oxidative stress have been firmly established by decades of research to enhance the effects of carcinogens in smoke [10]. Cigarette smoke initiates an inflammatory response that is critical in the pathogenesis of chronic obstructive pulmonary disease [11]. Inflammation and oxidative damage are also key mechanistic factors in the complex etiology of cardiovascular disease induced by cigarette smoking [11]. Oxidative and inflammatory response to cigarette smoke may also play an important role in the central nervous system pathogenic processes implicated in multiple neurological diseases [12]. Exposure to the toxic chemicals in tobacco smoke is also associated with hematological abnormalities such as increased mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), hematocrit and red cell count and reduced plasma volume [13,14].

The goal of this study was to examine biomarkers of inflammation, oxidative stress and hematological parameters that were analyzed from a large clinical trial [3], comparing smokers who underwent immediate versus gradual nicotine reduction in cigarettes; both of these conditions were compared to the control group who smoked normal nicotine content cigarettes. Prostaglandin E₂ metabolite (PGEM) and (Z)-7-[1R, 2R, 3R, 5S]-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid (8-iso-PGF_{2α}) are established biomarkers of oxidative damage and inflammation, respectively. Levels of these biomarkers and other biomarkers associated with inflammation and a panel of hematological biomarkers were monitored. We hypothesized that because reductions in toxicant exposure were observed in the immediate nicotine reduction condition compared to gradual nicotine reduction and control conditions, a similar pattern would be observed with these biomarkers of biological effects.

METHODS

Subjects

Daily smokers (≥ 5 cigarettes per day with no use of other tobacco or nicotine products > 9 out of past 30 days) who were of legal age for cigarette purchase [18 or 21 (San Francisco) years of age], in stable mental and physical health (assessed by self-reported medical and psychiatry history, PRIME-MD [15] and Center for Epidemiologic Studies Depression scale [16] that were reviewed by a licensed medical professional), not pregnant, planning to

become pregnant or breast-feeding and who reported no immediate intentions to quit smoking within the next 30 days (Stages of Change [17]) were recruited via advertisement at 10 US institutional sites.

Study design

Participants underwent screening following informed consent to determine eligibility. Eligible participants underwent 2 weeks of baseline smoking during which they smoked their own cigarettes. Participants were then randomly assigned in a double-blind manner to one of three Spectrum research cigarette [18] conditions: (1) immediate nicotine reduction to 0.4 mg/g tobacco ($n = 503$); (2) gradual nicotine reduction with doses decreasing from 15.5, 11.7, 5.2 and 2.4 to 0.4 mg nicotine/g ($n = 498$); or (3) normal nicotine dose of 15.5 mg/g serving as the control ($n = 249$). Randomization was stratified by site using the block randomization scheme with random block sizes of five or 10. An independent statistician used R [19] to generate the random numbers. Both menthol and non-menthol cigarettes were available. Smokers were assigned to these cigarettes for 5 months, with dose changes in the gradual nicotine reduction group occurring on a monthly basis (weeks 4, 8, 12 and 16).

Smoking amount during baseline and intervention was assessed using an interactive voice response (IVR) system that called participants each day to inquire about the number of cigarettes smoked on the previous day. During intervention, both study and non-study cigarettes were reported separately. Biological samples (first void urine brought by the participant to the clinic visit and blood drawn at the clinic visit) for all conditions were collected during baseline and just prior to the dose change visits that occurred in the gradual reduction group and at the last visit at week 20. See Hatsukami *et al.* [3] for more procedural details.

Compliance

In order to maximize compliance to only smoking study cigarettes, we required smokers to return full, partial or empty packs of cigarettes. Discrepancies between self-reported number of cigarettes on the IVR and packs that were returned were discussed with the participant. Participants were also told that they would receive a bonus payment if their randomly selected spot urines, collected at every visit, reflected the use of only study cigarettes. In actuality, only weeks 18 and 20 spot urines were analyzed for participants in the immediate or gradual nicotine reduction group, when both groups were assigned the 0.4 mg nicotine cigarette. Bonuses were paid if the total nicotine equivalents were < 12 nmol/ml, which allowed some, but minimal, conventional cigarette use. All participants in the normal nicotine content group were paid bonuses. Investigators

were notified if the participant did or did not earn the bonus (paid at the follow-up visit after intervention) determined by a staff member who was not affiliated with study conduct, therefore maintaining the double-blind condition. Partial bonuses were paid for honest reporting of use of non-study cigarettes.

Outcome measures

Urinary PGEM and 8-iso-PGF_{2α} were quantified by liquid chromatography–tandem mass spectrometry, as described previously [20]. Serum high-sensitivity C-reactive protein (hs-CRP) and hematological parameters were assessed by the Advanced Research and Diagnostic Laboratory at the University of Minnesota and the local institutional laboratories, respectively. 8-iso-PGF_{2α}, hs-CRP and white blood count (WBC, all biomarkers reflective of inflammation) were considered secondary end-points in our a priori statistical analysis plan [3]. PGEM and hematological parameters (red blood cell, mean corpuscular volume, etc.; see Table 1) were considered exploratory end-points. Primary end-points (related to biomarkers of exposure) were reported in the main article [3].

Statistical analysis

A total of 1250 participants were enrolled to ensure 80% power to detect an effect size of 0.4 between a reduction

group and control and 0.3 between the two reduction groups in any of the a priori primary end-points that were selected (see Hatsukami *et al.* [3] for more details). All analyses were performed using the intention-to-treat principle. Missing data were imputed by the Markov chain Monte Carlo (MCMC)-based multiple imputation (MI) method within each treatment group [23,24]. Proper transformation was applied to the outcome variables to achieve approximate normality in the MI for variables that were skewed, because the MCMC method assumes multivariate normality. To make the missing-at-random (MAR) assumption underlying the MI method more tenable in the presence of non-trivial missing rates, we incorporated a set of auxiliary variables in the MI procedure that were believed to be potentially associated with reasons for missing values and with the outcomes of interest [25,26]. These are age, gender, race, ethnicity, education, employment status, cigarettes per day, menthol, the Fagerström Test for Cigarette Dependence score, and serum nicotine metabolic ratio at baseline. Twenty imputed data sets were generated, with treatment effects being assessed in each imputed data set. A final single assessment of treatment effects was obtained from combining the results across the imputed data sets using adjusted degrees of freedom [27]. The last observation carried forward (LOCF) and baseline value carried forward imputation and no imputation (i.e. complete case analysis) were performed as sensitivity analyses.

Table 1 Mean or geometric mean of area under the curve by multiple imputation across intervention conditions.^a

End-point	Immediate	Gradual	Control
8-iso-PGF _{2α} AUC (pmol/mg creatinine), geometric mean	1.15	1.19	1.19
hs-CRP AUC (mg/l), geometric mean	2.74	3.01	2.53
hs-CRP AUC (mg/l), ≤ 10 only, ^b geometric mean	2.17	2.41	2.02
WBC AUC (10 ³ /μl), mean	7.55	7.71	7.47
WBC AUC (10 ³ /μl), ≤ 14 only, ^b mean	7.49	7.62	7.41
PGEM AUC (pmol/mg creatinine), geometric mean	57.25	57.55	60.46
Red cell count (10 ⁶ /μl), mean	4.73	4.77	4.70
Hemoglobin (g/dl), mean	14.23	14.28	14.22
Hematocrit (%), mean	43.00	43.13	42.86
MCV (fl), mean	91.16	90.72	91.50
MCH (pg), mean	30.13	29.98	30.26
MCHC (g/dl), mean	33.05	33.01	33.09
RDW (%), mean	13.86	14.00	13.98
Platelet count (10 ³ /μl), mean	246.39	243.73	244.71
MPV (fl), mean	10.00	10.03	9.84

^aUnadjusted mean or geometric mean of area under the curve for imputed data by using the Markov chain Monte Carlo (MCMC)-based multiple imputation method. ^bExclusion of out-of-range values. 8-iso-PGF_{2α} (pmol/mg) = (Z)-7-[1R,2R,3R,5S]-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid or 8-iso-prostaglandin F_{2α}; hs-CRP = high-sensitivity C-reactive protein, lower risk = 0–2 mg/l [21,22]; WBC (10³/μl) = white cell count, normal range = 3.8–11.0; PGEM (pmol/ml) = prostaglandin E metabolite; red cell count (10⁶/μl), normal range = female 3.75–5.40, male 4.10–6.20; hemoglobin (g/dl), normal range = female 11.5–16.0, male 12.5–18.0; hematocrit (%), normal range = female 34.8–47, male 36.0–54.0; MCV (fl) = mean corpuscular volume (measure of size of red blood cells), normal range = 80–100; MCH (pg) = mean corpuscular hemoglobin (quantity of hemoglobin in red blood cell), normal range = 27.0–34.0; MCHC (g/dl), mean corpuscular hemoglobin concentration (concentration of hemoglobin in red blood cells), normal range = 31.5–36.5; RDW (%), red blood cell distribution width (variation in size and volume of red blood cells), normal range = 11.0–15.6; platelet count (10³/μl), normal range = 140–440; MPV (fl), mean platelet volume (size of platelet), normal range = 7.0–12.4; AUC = area under the curve.

Area under the concentration time curve (AUC) during the 20-week period was calculated using the trapezoidal rule for the imputed data and then scaled by visit time (i.e. time-weighted average), and hence the unit of AUC is the same as the unit of its respective exposure variable. Unadjusted mean or geometric mean of AUC was calculated for each treatment. The primary analysis was linear regression for AUC (or log-AUC), adjusting for the baseline level (or log-level) of the biomarker. In a secondary analysis we additionally adjusted for the study site and any other baseline variables that differed between treatment groups at $P < 0.20$. For non-transformed AUC, the treatment effects are presented as adjusted mean difference (adjusted MD) in AUC; for log-AUC, the treatment effects are presented as the adjusted ratio of geometric means (adjusted RGM), which was calculated as the exponential of the adjusted MD in log-AUC. Additionally, we analyzed biomarkers measured at week 20 using the same linear regression methods as for the AUCs and the repeated measures at weeks 4, 8, 12, 16 and 20 using linear mixed models. The effects of study cigarettes that accounts for non-adherence was estimated using the compliance unsure re-weighted estimator (CURE) [28].

To study the relationship between consumption or exposure biomarkers with biological effects variables, we estimated their repeated-measure correlation (r_{rm}) using data at weeks 4, 8, 12, 16 and 20 from the immediate reduction group [29]. The exposure biomarkers selected included primary outcome variables in the original article [carbon monoxide, phenanthrene tetraol (PheT) and 3-HPMA [3]], indicators of different categories of constituents (total nicotine equivalents, total NNAL) and a biomarker that has been found to have stability over time and sensitivity to different tobacco products (CEMA) [3,30]. Biomarkers of biological effects represented different biological effect pathways (e.g. 8-iso-PGF_{2α}, PGEM, CRP, WBC and red blood cell distribution width (RDW)).

All tests were two-sided. Pairwise comparison P -values less than 0.00057 [= 0.05/(29 secondary end-points as described in our statistical analysis plan \times 3 pairwise comparisons per end-point)] for secondary end-points and 0.0167 [= 0.05/3 pairwise comparisons per end-point] for exploratory end-points. Bayes factors (BF) were calculated for the primary analysis, where a BF > 3 represents sufficient evidence for the effect, $< 1/3$ represents sufficient evidence for no effect, and between $1/3$ and 3 indicates an inconclusive finding [31,32]. Sensitivity analyses were conducted for WBC and hs-CRP by excluding values that were out of range (WBC $> 14 \times 10^3/\mu\text{l}$, hs-CRP $> 10 \text{ mg/l}$). The CURE analysis, the repeated-measure correlation analysis and the calculation of Bayes factors were performed using R [19]; all other analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

RESULTS

Participants smoked an average [standard deviation (SD)] of 17.1 (8.5) cigarettes per day at baseline and reported a mean (SD) Fagerström Test of Cigarette Dependence [33] score of 5.3 (2.1). They were comprised of 43.9% (549 of 1250) females, 60.6% (758 of 1250) white, with the other predominant self-reported race being black (29.8%, 373 of 1250), and had a mean age (SD) of 45.1 (13.4). No significant differences were observed for smoking history or demographics across groups. Significantly more dropouts were observed in the immediate reduction condition compared to the other two conditions [3]. When completers ($n = 958$) were compared to non-completers ($n = 292$), completers were significantly older [mean (SD) = 46.1 (13.3) versus 41.7 (13.2), $P < 0.001$]; had more females [n (%) = 441 (46) versus 108 (37), $P = 0.006$]; had fewer Hispanics [n (%) = 38 (4) versus 28 (10), $P < 0.001$]; had longer duration of smoking [mean (SD) = 28.0 (13.5) versus 23.8 (13.5) years, $P < 0.001$]; and had fewer who used other tobacco products [number (%) = 168 (21) versus 67 (28), $P = 0.018$]. See Hatsukami *et al.*, eTable 11 [3].

See Table 1 for AUC means or geometric means, Table 2 for AUC mean differences or ratio of geometric means and Table 3 for week 20 sensitivity analysis across groups.

For secondary end-points, significant difference was only observed for WBC when comparing AUC results for immediate versus gradual nicotine reduction; no significant differences were evident for other secondary end-point biomarkers when comparing AUC results for immediate versus gradual nicotine reduction, immediate nicotine reduction versus control or gradual nicotine reduction versus control. Week 20 sensitivity analysis produced similar findings as for AUC analysis, except no differences were observed across conditions for WBC.

For the exploratory end-points, the significantly lower AUC levels were observed between immediate versus gradual and immediate versus control for RDW, which measures variation in size and volume of red blood cells, with a trend toward similar results for week 20 sensitivity analysis. At week 20, significant differences were observed for MCV and MCH, with lower levels observed for immediate versus control and gradual versus control, but not for immediate versus gradual.

Causal effect analysis accounting for non-adherence (Supporting information, Table S1), AUC sensitivity analysis using LOCF, baseline value carried forward and complete case analysis (Supporting information, Table S2), sensitivity analysis using repeated measures over the course of 20 weeks (Supporting information, Table S3) and the Bayes factors calculated for the primary analysis (Supporting information, Table S4) generally produced similar results.

Table 2 Analysis of area under the curve (AUC)^a of biomarkers across interventions.

Measures	Immediate versus gradual		Immediate versus control		Gradual versus control	
	Mean difference/ratio of geometric means ^b (95% CI)	P-value ^c	Mean difference/ratio of geometric means ^b (95% CI)	P-value ^c	Mean difference/ratio of geometric means ^b (95% CI)	P-value ^c
Linear regression of AUC, adjusted for baseline ^d						
8-iso-PGF _{2α} (pmol/mg creatinine)	0.99 (0.95, 1.04)	0.69	0.96 (0.92, 1.01)	0.14	0.97 (0.92, 1.02)	0.28
hs-CRP (mg/l)	0.98 (0.91, 1.06)	0.61	1.06 (0.97, 1.17)	0.17	1.09 (0.99, 1.19)	0.078
hs-CRP (mg/l), ≤ 10 values only ^f	0.97 (0.91, 1.03)	0.27	1.04 (0.96, 1.13)	0.29	1.08 (1.00, 1.16)	0.045
WBC (10 ³ /μl)	−0.26 (−0.40, −0.12)	0.0004	−0.10 (−0.26, 0.07)	0.27	0.17 (0.00, 0.33)	0.056
WBC (10 ³ /μl), ≤14 values only ^f	−0.19 (−0.34, −0.05)	0.008	−0.13 (−0.29, 0.03)	0.10	0.06 (−0.10, 0.22)	0.45
PGEM (pmol/mg creatinine)	0.99 (0.92, 1.06)	0.73	0.94 (0.86, 1.02)	0.14	0.95 (0.87, 1.03)	0.23
Red cell count (10 ⁶ /μl)	−0.01 (−0.04, 0.01)	0.28	−0.01 (−0.04, 0.02)	0.52	0.00 (−0.02, 0.03)	0.78
Hemoglobin (g/dl)	−0.04 (−0.11, 0.04)	0.32	−0.06 (−0.15, 0.02)	0.14	−0.03 (−0.11, 0.06)	0.51
Hematocrit (%)	−0.12 (−0.34, 0.10)	0.27	−0.20 (−0.46, 0.06)	0.13	−0.08 (−0.33, 0.17)	0.54
MCV (fl)	−0.07 (−0.28, 0.14)	0.52	−0.23 (−0.48, 0.01)	0.061	−0.17 (−0.40, 0.07)	0.17
MCH (pg)	−0.01 (−0.09, 0.07)	0.79	−0.07 (−0.16, 0.02)	0.13	−0.06 (−0.15, 0.03)	0.21
MCHC (g/dl)	0.04 (−0.04, 0.11)	0.32	0.02 (−0.06, 0.10)	0.62	−0.02 (−0.10, 0.07)	0.71
RDW (%)	−0.11 (−0.18, −0.04)	0.004	−0.15 (−0.23, −0.06)	0.001	−0.04 (−0.12, 0.05)	0.43
Platelet count (10 ³ /μl)	−1.58 (−5.06, 1.89)	0.37	3.03 (−1.08, 7.14)	0.15	4.61 (0.61, 8.61)	0.024
MPV (fl)	0.07 (−0.08, 0.21)	0.36	0.02 (−0.09, 0.13)	0.74	−0.05 (−0.18, 0.09)	0.50
Linear regression of AUC, adjusted for baseline and other covariates ^e						
8-iso-PGF _{2α} (pmol/mg creatinine)	0.99 (0.95, 1.03)	0.60	0.96 (0.92, 1.01)	0.13	0.97 (0.93, 1.03)	0.32
hs-CRP (mg/l)	0.98 (0.91, 1.06)	0.66	1.07 (0.97, 1.17)	0.16	1.08 (0.99, 1.19)	0.083
hs-CRP (mg/l), ≤ 10 values only ^f	0.97 (0.91, 1.03)	0.31	1.04 (0.97, 1.13)	0.28	1.08 (1.00, 1.16)	0.050
WBC (10 ³ /μl)	−0.27 (−0.41, −0.13)	0.0002	−0.10 (−0.27, 0.07)	0.24	0.17 (0.00, 0.34)	0.049
WBC (10 ³ /μl), ≤14 values only ^f	−0.21 (−0.35, −0.06)	0.005	−0.14 (−0.30, 0.02)	0.089	0.07 (−0.09, 0.23)	0.40
PGEM (pmol/mg creatinine)	0.98 (0.92, 1.05)	0.65	0.94 (0.86, 1.02)	0.16	0.96 (0.88, 1.04)	0.29
Red cell count (10 ⁶ /μl)	−0.01 (−0.04, 0.01)	0.32	−0.01 (−0.04, 0.02)	0.47	0.00 (−0.02, 0.03)	0.89
Hemoglobin (g/dl)	−0.04 (−0.11, 0.04)	0.32	−0.07 (−0.16, 0.01)	0.10	−0.04 (−0.12, 0.05)	0.41
Hematocrit (%)	−0.12 (−0.34, 0.10)	0.27	−0.22 (−0.47, 0.04)	0.097	−0.09 (−0.34, 0.16)	0.46
MCV (fl)	−0.08 (−0.29, 0.12)	0.43	−0.24 (−0.49, 0.00)	0.049	−0.16 (−0.40, 0.08)	0.18
MCH (pg)	−0.01 (−0.10, 0.07)	0.73	−0.08 (−0.17, 0.02)	0.11	−0.06 (−0.16, 0.03)	0.20
MCHC (g/dl)	0.04 (−0.03, 0.11)	0.29	0.01 (−0.07, 0.09)	0.78	−0.03 (−0.11, 0.05)	0.52
RDW (%)	−0.11 (−0.18, −0.04)	0.003	−0.14 (−0.23, −0.06)	0.001	−0.03 (−0.12, 0.05)	0.45
Platelet count (10 ³ /μl)	−1.15 (−4.64, 2.33)	0.52	3.24 (−0.87, 7.36)	0.12	4.39 (0.37, 8.41)	0.032
MPV (fl)	0.06 (−0.08, 0.21)	0.37	0.02 (−0.09, 0.14)	0.67	−0.04 (−0.18, 0.10)	0.57

^aArea under the curve (AUC) scaled by time (i.e. time-weighted average); the unit is the same as its original variable. ^bMean difference for WBC, red cell count, hemoglobin, hematocrit, MCV, MCH, MCHC, RDW, platelet count and MPV; ratio of geometric means for 8-iso-PGF_{2α}, PGEM and hs-CRP. ^c $P < 0.00057$ were considered statistically significant for secondary end-points (8-iso-PGF_{2α}, hs-CRP and WBC); hs-CRP (≤ 10 values only) and WBC (≤ 14 values only) were analyzed as a sensitivity analysis for their respective non-restricted counterparts, hence the same P -value cut-off points were applied; $P < 0.0167$ were considered statistically significant for all the other biomarkers, which are exploratory end-points. ^dLinear regression of the AUC adjusted for the corresponding baseline measure of the biomarker; log-transformation was used for the AUC of 8-iso-PGF_{2α}, PGEM and hs-CRP and their baseline measure. ^eLinear regression of the AUC adjusted for the corresponding baseline measure of the biomarker study site, together with any baseline variables which were different between treatment arms at $P < 0.20$ (employment, Fagerström Test for Nicotine Dependence and serum nicotine metabolic ratio); log-transformation was used for the AUC of 8-iso-PGF_{2α}, PGEM, and hs-CRP. CI = confidence interval. ^fAnalysis conducted excluding out-of-range values. 8-iso-PGF_{2α} (pmol/mg) = (Z)-7-[1R,2R,3R,5S]-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid or 8-iso-prostaglandin F_{2α}; hs-CRP = high-sensitivity C-reactive protein; WBC (10³/μl) = white cell count; PGEM (pmol/ml) = prostaglandin E metabolite; MCV (fl) = mean corpuscular volume (measure of size of red blood cells); MCH (pg) = mean corpuscular hemoglobin (quantity of hemoglobin in red blood cell); MCHC (g/dl) = mean corpuscular hemoglobin concentration (concentration of hemoglobin in red blood cells); RDW (%) = red blood cell distribution (variation in size and volume of red blood cells); MPV (fl) = mean platelet volume (size of platelet).

Pairwise correlations between cigarettes per day and biomarkers associated with different categories of constituents with biomarkers associated with different pathways of

biological effects is shown in Supporting information, Table S5. Most notably, volatile organic compounds (CEMA, 3-HPMA), PheT and total NNAL had the most

Table 3 Analysis of biomarkers at week 20 across interventions (sensitivity analysis).

Measures	Immediate versus gradual		Immediate versus control		Gradual versus control	
	Mean difference/ratio of geometric means ^a (95% CI)	P-value ^b	Mean difference/ratio of geometric means ^a (95% CI)	P-value ^b	Mean difference/ratio of geometric means ^a (95% CI)	P-value ^b
Linear regression of week 20 biomarker, adjusted for baseline ^c						
8-iso-PGF _{2α} (pmol/mg creatinine)	0.98 (0.92, 1.05)	0.60	0.93 (0.85, 1.00)	0.060	0.94 (0.87, 1.02)	0.16
hs-CRP (mg/l)	0.99 (0.89, 1.10)	0.83	1.13 (0.99, 1.28)	0.062	1.14 (1.00, 1.29)	0.046
hs-CRP (mg/l), ≤ 10 values only ^c	0.99 (0.90, 1.09)	0.79	1.12 (0.99, 1.26)	0.064	1.13 (1.01, 1.27)	0.034
WBC (10 ³ /μl)	−0.16 (−0.38, 0.06)	0.16	−0.09 (−0.35, 0.17)	0.50	0.07 (−0.20, 0.34)	0.61
WBC (10 ³ /μl), ≤ 14 values only ^c	−0.10 (−0.32, 0.12)	0.38	−0.13 (−0.40, 0.14)	0.36	−0.03 (−0.27, 0.22)	0.83
PGEM (pmol/mg creatinine)	1.05 (0.94, 1.18)	0.39	1.02 (0.87, 1.18)	0.85	0.96 (0.84, 1.11)	0.61
Red cell count (10 ⁶ /μl)	0.00 (−0.04, 0.04)	0.92	0.01 (−0.03, 0.06)	0.52	0.01 (−0.03, 0.06)	0.56
Hemoglobin (g/dl)	0.00 (−0.12, 0.12)	0.97	−0.06 (−0.19, 0.07)	0.37	−0.06 (−0.19, 0.08)	0.39
Hematocrit (%)	0.01 (−0.34, 0.37)	0.94	−0.19 (−0.60, 0.21)	0.35	−0.21 (−0.60, 0.19)	0.30
MCV (fl)	−0.04 (−0.38, 0.31)	0.83	−0.68 (−1.08, −0.28)	<0.001	−0.64 (−1.03, −0.25)	0.001
MCH (pg)	−0.03 (−0.16, 0.10)	0.68	−0.23 (−0.38, −0.08)	0.003	−0.20 (−0.35, −0.05)	0.008
MCHC (g/dl)	0.03 (−0.08, 0.14)	0.55	0.02 (−0.10, 0.15)	0.72	−0.01 (−0.13, 0.11)	0.86
RDW (%)	−0.15 (−0.28, −0.03)	0.018	−0.21 (−0.34, −0.07)	0.003	−0.05 (−0.19, 0.09)	0.46
Platelet count (10 ³ /μl)	−2.56 (−8.35, 3.24)	0.38	2.64 (−4.00, 9.29)	0.43	5.20 (−1.07, 11.47)	0.10
MPV (fl)	0.03 (−0.11, 0.18)	0.64	−0.01 (−0.14, 0.12)	0.88	−0.04 (−0.19, 0.10)	0.54
Linear regression of week 20 biomarker, adjusted for baseline and other covariates ^d						
8-iso-PGF _{2α} (pmol/mg creatinine)	0.98 (0.91, 1.04)	0.47	0.92 (0.85, 1.00)	0.051	0.95 (0.87, 1.03)	0.19
hs-CRP (mg/l)	0.99 (0.89, 1.10)	0.84	1.13 (1.00, 1.28)	0.053	1.14 (1.01, 1.30)	0.041
hs-CRP (mg/l), ≤ 10 values only ^c	0.99 (0.90, 1.09)	0.86	1.12 (1.00, 1.26)	0.059	1.13 (1.01, 1.27)	0.038
WBC (10 ³ /μl)	−0.18 (−0.40, 0.05)	0.13	−0.11 (−0.37, 0.16)	0.43	0.07 (−0.20, 0.34)	0.62
WBC (10 ³ /μl), ≤ 14 values only ^c	−0.11 (−0.34, 0.11)	0.32	−0.14 (−0.40, 0.13)	0.31	−0.03 (−0.27, 0.22)	0.84
PGEM (pmol/mg creatinine)	1.05 (0.93, 1.18)	0.41	1.01 (0.87, 1.18)	0.87	0.96 (0.84, 1.11)	0.60
Red cell count (10 ⁶ /μl)	0.00 (−0.04, 0.04)	0.90	0.01 (−0.03, 0.06)	0.56	0.01 (−0.03, 0.05)	0.63
Hemoglobin (g/dl)	0.00 (−0.12, 0.12)	0.97	−0.07 (−0.20, 0.06)	0.31	−0.07 (−0.20, 0.07)	0.34
Hematocrit (%)	0.02 (−0.34, 0.38)	0.92	−0.21 (−0.61, 0.20)	0.32	−0.23 (−0.62, 0.17)	0.26
MCV (fl)	−0.08 (−0.39, 0.30)	0.80	−0.68 (−1.09, −0.28)	<0.001	−0.64 (−1.03, −0.25)	0.001
MCH (pg)	−0.03 (−0.16, 0.10)	0.70	−0.23 (−0.38, −0.08)	0.003	−0.20 (−0.35, −0.06)	0.007
MCHC (g/dl)	0.03 (−0.07, 0.14)	0.53	0.01 (−0.11, 0.14)	0.85	−0.02 (−0.14, 0.10)	0.71
RDW (%)	−0.15 (−0.28, −0.03)	0.018	−0.21 (−0.34, −0.07)	0.003	−0.05 (−0.19, 0.09)	0.47
Platelet count (10 ³ /μl)	−2.12 (−7.98, 3.74)	0.47	2.59 (−4.03, 9.22)	0.44	4.71 (−1.66, 11.09)	0.15
MPV (fl)	0.03 (−0.12, 0.18)	0.68	−0.01 (−0.13, 0.12)	0.94	−0.04 (−0.18, 0.11)	0.63

^aMean difference for WBC, red cell count, hemoglobin, hematocrit, MCV, MCH, MCHC, RDW, platelet count and MPV; ratio of geometric means for 8-iso-PGF_{2α}, PGEM and hs-CRP. ^b $P < 0.00057$ were considered statistically significant for secondary end-points (8-iso-PGF_{2α}, hs-CRP, and WBC); hs-CRP (≤ 10 values only) and WBC (≤ 14 values only) were analyzed as a sensitivity analysis for their respective non-restricted counterparts, hence the same P -value cut-off points were applied; $P < 0.0167$ were considered statistically significant for all the other biomarkers which are exploratory end-points. ^cLinear regression of the week 20 biomarker adjusted for the corresponding baseline measure; log-transformation was used for 8-iso-PGF_{2α}, PGEM and hs-CRP. ^dLinear regression of the week 20 biomarker adjusted for the corresponding baseline measure, study site, together with any baseline variables which were different between treatment arms at $P < 0.20$ (employment, Fagerström Test for Nicotine Dependence and serum nicotine metabolic ratio); log-transformation was used for 8-iso-PGF_{2α}, PGEM and hs-CRP. CI = confidence interval. ^eAnalysis conducted excluding out-of-range values. 8-iso-PGF_{2α} (pmol/mg) = (Z)-7-[1R,2R,3R,5S]-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid) or 8-iso-prostaglandin F_{2α}; hs-CRP = high-sensitivity C-reactive protein; WBC (10³/μl) = white cell count; PGEM (pmol/ml) = prostaglandin E metabolite; MCV (fl) = mean corpuscular volume (measure of size of red blood cells); MCH (pg) = mean corpuscular hemoglobin (quantity of hemoglobin in red blood cell); MCHC (g/dl) = mean corpuscular hemoglobin concentration (concentration of hemoglobin in red blood cells); RDW (%) = red blood cell distribution (variation in size and volume of red blood cells); MPV (fl) = mean platelet volume (size of platelet).

significant correlations with biomarkers of biological effect (8-iso-PGF_{2α}, PGEM, CRP, WBC and/or RDW), but the correlation coefficients were modest at best (the highest correlation coefficient was 0.20).

DISCUSSION

Few biomarkers associated with adverse health effects showed differences across the experimental groups. A

biomarker that was consistently significant across primary and sensitivity analysis was RDW%, which followed the pattern that was observed with biomarkers of exposures; that is, lower levels in the immediate versus gradual nicotine reduction and control groups. A few other hematological parameters demonstrated significant difference: AUC for WBC was lower in the immediate versus gradual condition but not at week 20, and week 20 sensitivity analysis for MCV and MCH was lower in the immediate and gradual

versus control condition. The findings of the other studied biomarkers were either inconclusive or showed no difference based on the Bayes factors analysis.

The literature typically shows higher levels in smokers versus non-smokers on these parameters [13,35–39]. The mechanism of hematological changes associated with smoking is not wholly understood, and can be a combination of multiple factors. Smoking is associated with inflammation and generation of free radicals, which can damage red blood cells, resulting in increased levels of immature RBC contributing to higher RDW [40–42]. Increased RDW has been associated with increased morbidity and mortality in patients with chronic heart failure [43], prior myocardial infarction [44] and mortality in older adults with or without age-related disease [45]. Increased white blood cell count has similarly been associated with smoking-induced inflammation and related to increased cardiovascular disease [34,46,47]. In our study immediate nicotine reduction was associated with an overall greater decrease in cigarette smoking and exposures to oxidant chemicals compared to the other conditions (see Supporting information, Fig. S1), which could explain the effect on RDW and WBC. Increased MCH values most probably result from the body's compensatory response to hypoxia induced by exposures to carbon monoxide and possibly para-benzoquinone from smoking [48–50]. In our study both nicotine reduction approaches were associated with lower carbon monoxide exposures compared to the control group at week 20, which could explain the effect on MCV and MCH.

Overall, the results from this study demonstrate that although significant reductions occur in cigarettes per day and biomarkers of exposure with reduced nicotine content cigarettes [3], these cigarettes might still be associated with significant health risks related to harmful chemical exposure. Reductions in biomarkers of exposure (e.g. total NNAL, PheT, CEMA) are related to toxicant dose, whereas biomarkers of potential harm are related to alterations of biological processes (e.g. inflammation, oxidative stress) that are involved in disease etiology and are affected by cigarette smoking. Several studies have demonstrated that there were only modest reductions in PGEM and 8-iso-PGF_{2α} when subjects stopped smoking for 3 months to 1 year [51–53]. These findings suggest that these biomarkers might take longer to show substantial reductions, that it is difficult to achieve complete reversal once these biological alterations have occurred, or that other factors in smokers may be contributing to the increase in inflammation and oxidative stress. As a further explanation, the dose–response for cigarette smoke exposure with response to some of the biomarkers of potential harm, as well as cardiovascular disease risk, is well known to be non-linear. Thus, secondhand smoke exposure produces 80–90% of the impact on cardiovascular biomarkers compared to

active smoking [54]. Similarly, the risk of acute cardiovascular events is disproportionately high with exposure to secondhand smoke or when smoking a few cigarettes per day compared to heavy smoking. [55] Thus, it is not surprising that reduction of toxicant exposure while smoking reduced nicotine content cigarettes did not produce a beneficial effect of cardiovascular disease biomarkers. Therefore, a substantially greater reduction in exposures than observed with VLNC cigarettes might be necessary to see a reduction in biomarkers associated with significant health problems, which might account for the modest dose–response effects observed between biomarkers of constituent exposure and biomarkers of biological effect. It is also possible that the reductions in these biomarkers were not observed because of the high rate of non-compliance to only using study cigarettes (i.e. use of usual brand cigarettes). Nevertheless, the effects of immediate nicotine reduction on RDW suggest a possible beneficial effect on cardiovascular disease risk and mortality, although the magnitude in reduction in RDW was small and of uncertain clinical significance.

If nicotine in cigarettes were to become regulated, it would be imperative to educate the consumer that this product standard is not associated with a significant reduction in cigarette harm. Smokers tend to report misperceptions of the harms of cigarettes that are significantly reduced in levels of nicotine [56–59]. These misperceptions are due largely to the erroneous belief that nicotine causes cancer or heart disease and, therefore, if nicotine is reduced in a product, then it would be safer. Although nicotine is the primary agent that causes addiction [11] and is associated with potential harm to the fetus, increased risk of cardiovascular disease and possible negative effects on the adolescent brain, the vast majority of the negative health effects are associated combustion-derived constituents in tobacco smoke [10]. Therefore, the primary goal of reducing nicotine in cigarettes to minimally addictive levels would not be to reduce smoking amount, but rather to facilitate quitting in smokers and prevent uptake of smoking in youth and young adults. To this end, regulating nicotine in cigarettes, should it be found to be feasible and effective as a means of reducing smoking, must be a part of a comprehensive tobacco control program that continues to increase taxes on cigarettes, bans smoking in all public places, offers accessible and affordable treatments and effectively utilizes anti-smoking media campaigns.

Clinical trial registration

NCT: 02139930.

Declaration of interests

N.L.B. has been a consultant to Pfizer and Achieve Life Sciences, companies that market or are developing smoking

cessation medications, and has been a paid expert witness in litigation against tobacco companies. P.M.C. served on the scientific advisory board of Pfizer Pharmaceuticals, conducted educational talks sponsored by Pfizer on smoking cessation (2006–08) and has received grant support from Pfizer. D.J.D. serves as a paid expert witness in litigation against tobacco companies. A.A.S. has received grant support through the Pfizer GRAND grant funding program. The other authors have nothing to declare.

Acknowledgements

This study was funded by National Institute on Drug Abuse and Food and Drug Administration grant U54DA031659. All mass spectrometry was conducted in the Analytical Biochemistry Shared Resource of the Masonic Cancer Center, supported in part by National Cancer Institute Cancer Center Support grant P30CA07759. REDCap (Research Electronic Data Capture) services were provided by grant UL1TR000114 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health. Clinical services at the University of Minnesota site were provided by grant UL1TR002494 from the Clinical Translational Science Award of the National Institutes of Health. We are grateful to the staff, students and investigators who implemented the study and Kathy Longley for her many years of service and contributions to preparing this paper. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Food and Drug Administration.

Authors' affiliations

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA,¹ Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA,² Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA,³ Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA,⁴ Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, USA,⁵ Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, FL, USA,⁶ Department of Psychiatry, Philadelphia, University of Pennsylvania, PA, USA,⁷ Behavioral Medicine Laboratories, University of Minnesota Medical School, Duluth, MN, USA,⁸ Mayo Clinic, Health Sciences Research, Scottsdale, AZ, USA,⁹ Department of Medicine, University of California, San Francisco, CA, USA¹⁰ and Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, USA¹¹

References

- Food and Drug Administration *Tobacco Product Standard for Nicotine Level of Combusted Cigarettes*. Washington, DC: Federal Register; 2018, pp. 11818–43.
- Apelberg B. J., Feirman S. P., Salazar E., Corey C. G., Ambrose B. K., Paredes A. *et al.* Potential public health effects of reducing nicotine levels in cigarettes in the United States. *N Engl J Med* 2018; **378**: 1725–33.
- Hatsukami D. K., Luo X., Jensen J. A., al'Absi M., Allen S. S., Carmella S. G. *et al.* Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure: a randomized clinical trial. *JAMA* 2018; **320**: 880–91.
- Hatsukami D. K., Kotlyar M., Hertsgaard L. A., Zhang Y., Carmella S. G., Hatsukami D. K. *et al.* Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. *Addiction* 2010; **105**: 343–55.
- Donny E. C., Denlinger R. L., Tidey J. W., Koopmeiners J. S., Benowitz N. L., Vandrey R. G. *et al.* Randomized trial of reduced-nicotine standards for cigarettes. *N Engl J Med* 2015; **373**: 1340–9.
- Hatsukami D., Donny E. C., Koopmeiners J. S., Benowitz N. L. Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. *Cancer Epidemiol Biomark Prev* 2015; **24**: 472–6.
- Higgins, Heil S. H., Sigmon S. C., Tidey J. W., Gaalema D. E., Stitzer M. L. *et al.* Response to varying the nicotine content of cigarettes in vulnerable populations: an initial experimental examination of acute effects. *Psychopharmacology (Berl)* 2017; **234**: 89–98.
- Strasser A. A., Lerman C., Sanborn P. M., Pickworth W. B., Feldman E. A. New lower nicotine cigarettes can produce compensatory smoking and increased carbon monoxide exposure. *Drug Alcohol Depend* 2007; **86**: 294–300.
- Stratton K., Shetty P., Wallace R., Bondurant S. *editors. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction*. Institute of Medicine. Washington, DC: National Academy Press; 2001.
- US Department of Health and Human Services *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
- US Department of Health and Human Services *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
- Khanna A., Guo M., Mehra M., Royal W. III Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains. *J Neuroimmunol* 2013; **254**: 69–75.
- Malenica M., Prnjavorac B., Bego T., Dujic T., Semiz S., Skrbic S. *et al.* Effect of cigarette smoking on haematological parameters in healthy population. *Med Arch* 2017; **71**: 132–6.
- Smith J. R., Landaw S. A. Smokers' polycythemia. *N Engl J Med* 1978; **298**: 6–10.
- Spitzer R. L., Williams J. B., Kroenke K., Linzer M., deGruy F. V. 3rd, Hahn S. R. *et al.* Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. *JAMA* 1994; **272**: 1749–56.
- Radloff L. S. The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Measur* 1977; **1**: 385–401.
- Prochaska J. O., Velicer W. F., DiClemente C. C., Fava J. Measuring process of change: applications to the cessation of smoking. *J Consult Clin Psychol* 1988; **56**: 520–8.
- Nicotine research cigarettes drug supply program 2016. Available at: <https://www.drugabuse.gov/nicotine-research-cigarette-drug-supply-program> (accessed 1 August 2018)

19. R Core Team R: *a language and environment for statistical computing*. Vienna, Austria: R Foundation for Statistical Computing; 2017.
20. Carmella S. G., Heskin A. K., Tang M. K., Jensen J., Lou X., Le C. T. *et al.* Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. *PLoS One* 2019; **14**: e0215853.
21. Hutchinson K. Laboratory procedure manual - C-reactive protein. 2011 University of Washington Medical Center 2011. Available at: https://www.cdc.gov/NCHS/data/nhanes/nhanes_09_10/CRP_F_met.pdf (accessed 2018 October 22).
22. Stoppler MC. C-reactive protein test. Mayo Clinic. 2019. Available at: <https://www.mayoclinic.org/tests-procedures/c-reactive-protein-test/about/pac-20385228?p=1> (accessed 2018 October 22).
23. Little R. J. A., Rubin D. B. *Statistical Analysis with Missing Data*, 2nd edn. Hoboken, NJ: Wiley; 2002xv, p. 381.
24. Schafer J. L. *Analysis of Incomplete Multivariate Data*. London: Chapman & Hall; 1997.
25. Little R. J., D'Agostino R., Cohen M. L., Dickersin K., Emerson S. S., Farrar J. T. *et al.* The prevention and treatment of missing data in clinical trials. *N Engl J Med* 2012; **367**: 1355–60.
26. National Research Council *The Prevention and Treatment of Missing Data in Clinical Trials*, Vol. 162. Washington, DC: The National Academies Press; 2010.
27. Barnard J., Rubin D. B. Small-sample degrees of freedom with multiple imputation. *Biometrika* 1999; **84**: 948–55.
28. Boatman J. A., Vock D. M., Koopmeiners J. S., Donny E. C. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error. *Biostatistics* 2018; **19**: 103–18.
29. Bakdash J. Z., Marusich L. R. Repeated measures correlation. *Front Psychol* 2017; **8**: 456.
30. Chen M., Carmella S. G., Sipe C., Jensen J., Luo X., Le C. T. *et al.* Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. *PLOS ONE* 2019; **14**: e0210104.
31. Beard E., Dienes Z., Muirhead C., West R. Using Bayes factors for testing hypotheses about intervention effectiveness in addictions research. *Addiction* 2016; **111**: 2230–47.
32. Bayes CJ. Factor calculator. R code 2011. 2019. Available at: http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference (accessed 25 April 2019).
33. Fagerstrom K. Determinants of tobacco use and renaming the FTND to the Fagerstrom test for cigarette dependence. *Nicotine Tob Res* 2012; **14**: 75–8.
34. Yanbaeva D. G., Dentener M. A., Creutzberg E. C., Wesseling G., Wouters E. F. Systemic effects of smoking. *Chest* 2007; **131**: 1557–66.
35. McKarns S. C., Smith C. J., Payne V. M., Doolittle D. J. Blood parameters associated with atherogenic and thrombotic risk in smokers and nonsmokers with similar life-styles. *Mod Pathol* 1995; **8**: 434–40.
36. Kurtoglu E., Akturk E., Korkmaz H., Sincer I., Yilmaz M., Erdem K. *et al.* Elevated red blood cell distribution width in healthy smokers. *Turk Kardiyol Dern Ars* 2013; **41**: 199–206.
37. Van Tiel E., Peeters P., Smit H., Nagelkerke N., Van Loon A., Grobbee D. *et al.* Quitting smoking may restore hematological characteristics within five years. *Ann Epidemiol* 2002; **12**: 377–88.
38. Helman N., Rubenstein L. S. The effects of age, sex, and smoking on erythrocytes and leukocytes. *Am J Clin Pathol* 1975; **63**: 35–44.
39. Whitehead T. P., Robinson D., Allaway S. L., Hale A. C. The effects of cigarette smoking and alcohol consumption on blood haemoglobin, erythrocytes and leucocytes: a dose related study on male subjects. *Clin Lab Haematol* 1995; **17**: 131–8.
40. Lymperaki E., Makedou K., Iliadis S., Vagdatli E. J. H. Effects of acute cigarette smoking on total blood count and markers of oxidative stress in active and passive smokers. *Hippokratia* 2015; **19**: 293.
41. Levitzky Y. S., Guo C.-Y., Rong J., Larson M. G., Walter R. E., Keaney J. F. *et al.* Relation of smoking status to a panel of inflammatory markers: the Framingham offspring. *Atherosclerosis* 2008; **201**: 217–24.
42. Mehlhorn R. J. Increased vulnerability of human erythrocytes to hydroperoxide damage after exposure to cigarette smoke or 1-chloro-2,4-dinitrobenzene in vitro. *Nicotine Tob Res* 2000; **2**: 141–8.
43. Felker G. M., Allen L. A., Pocock S. J., Shaw L. K., McMurray J. J., Pfeffer M. A. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. *J Am Coll Cardiol* 2007; **50**: 40–7.
44. Tonelli M., Sacks F., Arnold M., Moye L., Davis B., Pfeffer M. *et al.* For the cholesterol and recurrent events (CARE) trial investigators. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. *Circulation* 2008; **117**: 163–8.
45. Patel K. V., Semba R. D., Ferrucci L., Newman A. B., Fried L. P., Wallace R. B. *et al.* Red cell distribution width and mortality in older adults: a meta-analysis. *J Gerontol A Biol Sci Med Sci* 2010; **65**: 258–65.
46. Higuchi T., Omata F., Tsuchihashi K., Higashioka K., Koyamada R., Okada S. Current cigarette smoking is a reversible cause of elevated white blood cell count: cross-sectional and longitudinal studies. *Prev Med Rep* 2016; **4**: 417–22.
47. Lee Y. J., Lee J. W., Kim J. K., Lee J. H., Kim J. H., Kwon K. Y. *et al.* Elevated white blood cell count is associated with arterial stiffness. *Nutr Metab Cardiovasc Dis* 2009; **19**: 3–7.
48. Mitra A., Mandal A. K. Conjugation of para-benzoquinone of cigarette smoke with human hemoglobin leads to unstable tetramer and reduced cooperative oxygen binding. *J Am Soc Mass Spectrom* 2018; **29**: 2048–58.
49. Papathanasiou G., Mamali A., Papafloratos S., Zerva E. Effects of smoking on cardiovascular function: the role of nicotine and carbon monoxide. *Health Sci J* 2014; **8**: 272–88.
50. Pollini G., Maugeri U., Bernardo A., Bianchi I., Flak E., Jedrychowski W. Erythrocytes parameters due to aging, smoking, alcohol consumption and occupational activity in a working population of petrochemical industry. The Pavia study. *G Ital Med Lav* 1989; **11**: 237–40.
51. Reilly M., Delanty N., Lawson J. A., FitzGerald G. A. Modulation of oxidant stress *in vivo* in chronic cigarette smokers. *Circulation* 1996; **94**: 19–25.
52. King C. C., Piper M. E., Gepner A. D., Fiore M. C., Baker T. B., Stein J. H. Longitudinal impact of smoking and smoking cessation on inflammatory markers of cardiovascular disease risk. *Arterioscler Thromb Vasc Biol* 2017; **37**: 374–9.
53. Goettel M., Niessner R., Scherer M., Scherer G., Pluym N. Analysis of urinary eicosanoids by LC-MS/MS reveals alterations in the metabolic profile after smoking cessation. *Chem Res Toxicol* 2018; **31**: 176–82.
54. Barnoya J., Glantz S. A. Cardiovascular effects of secondhand smoke: nearly as large as smoking. *Circulation* 2005; **111**: 2684–98.

55. Institute of Medicine (US) Committee on Secondhand Smoke Exposure and Acute Coronary Events *Secondhand Smoke Exposure and Cardiovascular Effects: Making Sense of the Evidence*. Washington, DC: National Academies Press; 2010.
56. Mercincavage M., Saddleson M. L., Gup E., Halstead A., Mays D., Strasser A. A. Reduced nicotine content cigarette advertising: how false beliefs and subjective ratings affect smoking behavior. *Drug Alcohol Depend* 2017; **173**: 99–106.
57. Denlinger-Apte R. L., Joel D. L., Strasser A. A., Donny E. C. Low nicotine content descriptors reduce perceived health risks and positive cigarette ratings in participants using very low nicotine content cigarettes. *Nicotine Tob Res* 2017; **19**: 1149–54.
58. O'Brien E. K., Nguyen A. B., Persoskie A., Hoffman A. C. U.S. adults' addiction and harm beliefs about nicotine and low nicotine cigarettes. *Prev Med* 2017; **96**: 94–100.
59. Byron M. J., Jeong M., Abrams D. B., Brewer N. T. Public misperception that very low nicotine cigarettes are less carcinogenic. *Tob Control* 2018; **27**: 712–4.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1 Estimated causal effect¹ adjusting for covariates associated with the outcome.

Table S2 Analysis of Area Under the Curve (AUC)¹ of biomarkers across interventions, sensitivity analysis with last observation carried forward (LOCF) imputation, baseline value carried forward imputation, and complete case analysis.

Table S3 Analysis of biomarkers over 20 weeks across interventions, sensitivity analysis with repeated measures analysis.

Table S4 Bayes Factors for the primary analysis¹ of Area Under the Curve (AUC) of biomarkers across interventions.

Table S5 Pairwise correlations between consumption or exposure variables with biological effect variables, using repeated measures data.

Figure S1 Cigarettes per day, 2-cyanoethylmercapturic acid (CEMA; biomarker for exposure to acrylonitrile) and carbon monoxide (modified from reference 3).